Is Sermorelin FDA Approved? 503A Status Explained

Sermorelin: What It Is, What the Research Shows, and Its FDA Status

By Medical Team of Generic Peptides

Quick answer. Sermorelin is a synthetic copy of the first 29 amino acids of human growth hormone–releasing hormone (GHRH 1-29). It was FDA-approved under the brand name Geref — as a diagnostic in 1990 and as a treatment for children with idiopathic growth hormone deficiency in 1997 [10]. The manufacturer stopped making it in 2008, and in 2013 FDA formally determined that Geref was not withdrawn for reasons of safety or effectiveness [9]. No FDA-approved sermorelin product is marketed in the US today. Sermorelin is not a controlled substance, it was not among the peptides FDA restricted for compounding in 2023 [12], and it is prohibited in sport by WADA [13].

What Is Sermorelin?

Sermorelin is a 29-amino-acid peptide with a C-terminal amide and a molecular weight of about 3,358 Da. Its sequence is identical to residues 1–29 of endogenous human GHRH, the hypothalamic hormone that tells the pituitary to release growth hormone.

The full 44-residue hormone was isolated in 1982 from pancreatic tumors that had caused acromegaly, by the groups of Roger Guillemin and Jean Rivier [6, 7]. Researchers soon found that the first 29 residues carry the full biological activity. That fragment became sermorelin — the shortest fully active form of GHRH.

Sermorelin is sometimes confused with MOD GRF 1-29 (also sold as CJC-1295 without DAC). They share the same 1–29 backbone, but MOD GRF carries four amino acid substitutions that make it resistant to enzymatic breakdown. Sermorelin is the unmodified native sequence.

How Sermorelin Works

Sermorelin binds the GHRH receptor on somatotroph cells of the anterior pituitary. This raises intracellular cAMP and triggers both release of stored growth hormone and transcription of new GH.

Three features shape how it behaves in research:

• It works upstream of GH. Sermorelin does not replace growth hormone; it asks the pituitary to make its own. The response depends on a functioning pituitary.
• Feedback stays intact. GH release still follows the body's pulsatile pattern and remains under the brake of somatostatin and IGF-1 feedback. This is the main pharmacological difference from administering recombinant GH.
• It is short-lived. Native GHRH 1-29 is degraded within minutes by the enzyme DPP-4 and other peptidases. That short half-life is why longer-acting analogs such as MOD GRF 1-29, CJC-1295 with DAC and tesamorelin were developed.

What the Research on Sermorelin Shows

Most sermorelin data come from the 1990s, when it was a licensed drug. The evidence falls into three groups.

Children with growth hormone deficiency (human, the approval data)

The pivotal study was an open-label multicenter trial by the Geref International Study Group. It enrolled 110 prepubertal children with GH deficiency, of whom 86 were analyzed. Once-daily sermorelin roughly doubled mean height velocity at 6 and 12 months, with no significant adverse changes reported [1]. These results supported the 1997 approval. Reviews from the same period noted that recombinant GH produced larger growth responses, which is part of why sermorelin never became a first-line treatment [2].

Older adults (human, small studies)

Ageing is associated with a fall in GH secretion, and several groups asked whether GHRH could restore it.

• Corpas et al., 1992: 10 older men were compared with 9 young men. Fourteen days of twice-daily GHRH 1-29 raised the older men's GH and IGF-1 to levels similar to the young group, with no change in glucose, insulin, blood pressure or blood counts [3].
• Vittone et al., 1997: 11 men aged 64–76 received six weeks of nightly sermorelin in an uncontrolled study. Night-time GH rose, but IGF-1 and body composition measured by DEXA did not change. Two of six strength measures improved, and no adverse events were recorded. The authors concluded that a single nightly dose was less effective than repeated doses [4].
• Khorram et al., 1997: 19 adults aged 55–71 received a closely related GHRH 1-29 analog nightly for 16 weeks after a placebo lead-in. GH, IGF-1 and lean body mass rose in both sexes; bone density did not change [5].

What the evidence does not show

These are small, short studies from a single era, mostly without placebo controls. There is no large randomized trial of sermorelin in adults with muscle mass, strength or long-term safety as the primary endpoint. Reviews of GH secretagogues as a class describe them as generally well tolerated, with a possible effect on blood glucose, and note that long-term controlled data are lacking [8]. Claims about sermorelin for anti-ageing, fat loss or muscle growth in adults go beyond what these studies measured.

Is Sermorelin FDA Approved?

It was — and the approval history matters more than for most peptides.

The 2013 determination was issued in response to a citizen petition. Its practical effect is that FDA may approve generic (ANDA) versions referencing Geref if other requirements are met [9]. As of October 2026, no such generic has been approved, and no FDA-approved sermorelin product is on the US market.

So the accurate short answer to "is sermorelin FDA approved" is: it was approved, it was discontinued for non-safety reasons, and it is not currently marketed as an approved drug.

Is Sermorelin Legal? Compounding, Controlled-Substance and Sport Status

Compounding. Under section 503A of the Food, Drug, and Cosmetic Act, a pharmacy may compound with a bulk drug substance only if it has a USP or NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list [11]. Compounders and regulatory lawyers generally place sermorelin in the second group because of the Geref approvals. FDA has not issued a sermorelin-specific statement on this point.

Not in the 2023 restrictions. In September 2023 FDA moved 19 peptides — including BPC-157, CJC-1295, ipamorelin, TB-500 and Semax — into Category 2 of its interim bulks policy, which effectively barred their use in compounding. Sermorelin was not on that list or in any other category [12]. It was also not among the peptides reviewed at FDA's advisory committee meeting in July 2026.

Controlled substance. Sermorelin is not scheduled under the US Controlled Substances Act.

Sport. WADA lists growth hormone–releasing hormone and its analogs among prohibited substances at all times, and USADA treats sermorelin accordingly [13].

Regulatory status is a question about drugs for patients. Research-grade sermorelin sold by chemical suppliers is a different category: it is labeled for laboratory research use only and is not intended for human consumption.

Sermorelin vs Other GHRH Analogs

For the differences in detail, see our guides to MOD GRF 1-29 and tesamorelin.

What to Check on a Research-Grade Sermorelin COA

Because sermorelin and MOD GRF 1-29 share most of their sequence, identity testing matters. A useful certificate of analysis should show the full sequence, a mass-spectrometry result matching about 3,358 Da (MOD GRF 1-29 is about 3,368 Da, so the difference is small and the spectrum should be shown), HPLC purity with the chromatogram, and the lot number that matches the vial. Our guide to reading a research peptide COA explains each section. Research-grade sermorelin from Generic Peptides ships with a lot-specific COA.

FAQ

Is sermorelin FDA approved?

Sermorelin was FDA-approved as Geref in 1990 (diagnostic) and 1997 (treatment of GH deficiency in children). It was discontinued in 2008, and FDA determined in 2013 that it was not withdrawn for safety or effectiveness reasons. No approved sermorelin product is currently marketed in the US.

What is sermorelin?

Sermorelin is the 29-amino-acid active fragment of human growth hormone–releasing hormone. It stimulates the pituitary to release its own growth hormone rather than replacing GH directly.

Is sermorelin a controlled substance?

No. Sermorelin is not scheduled under the US Controlled Substances Act. It is, however, prohibited in sport by WADA.

Is sermorelin the same as MOD GRF 1-29 or CJC-1295?

No. All three share the GHRH 1-29 backbone, but MOD GRF 1-29 carries four amino acid substitutions that slow its breakdown, and CJC-1295 with DAC adds a linker that binds albumin. Sermorelin is the unmodified native sequence.

Why was Geref discontinued?

The manufacturer stopped production in 2008. FDA's 2013 Federal Register determination states the product was not withdrawn for reasons of safety or effectiveness.

References

For research use only. Not for human consumption. This content is for informational purposes and is not medical advice.